This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and urine samples of NSCLC patients.
Liquid biopsy, specifically through the assessment of circulating tumor DNA(ctDNA) from peripheral blood, has shown great promise in lung cancer diagnosis and therapeutic monitoring. Urinary samples are completely non-invasive and easily obtainable compared to blood and tissue extraction. To date, only a limited number of published studies have examined the feasibility of ctDNA detection from urine. This study will collect tumor tissues, pretreatment peripheral blood samples and urine samples from different TNM stages of NSCLC patients, and detect EGFR gene mutations in paired samples.
Study Type
OBSERVATIONAL
Enrollment
45
Peking University People'S Hospital
Beijing, Beijing Municipality, China
The concordant frequency of genomic results among tumor tissue DNA, urinary ctDNA and peripheral blood ctDNA.
Time frame: 12 months
The difference of urine ctDNA detection effectiveness between different TNM stages NSCLC patients.
Time frame: 18 months
Correlation of urine ctDNA concentration preoperative,intraoperative and 3 days after surgery with clinical features and prognosis.
Time frame: 18 months
Lead time of tumor relapse detection by urine ctDNA than tumor markers and radiographic approaches.
Time frame: 3 years
Urinary ctDNA predictive value for locoregional recurrence and distant metastasis.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.